Atossa Genetics Inc. (ATOS): Price and Financial Metrics
ATOS Price/Volume Stats
| Current price | $0.96 | 52-week high | $2.31 |
| Prev. close | $0.98 | 52-week low | $0.72 |
| Day low | $0.96 | Volume | 1,088,800 |
| Day high | $1.02 | Avg. volume | 1,064,690 |
| 50-day MA | $1.32 | Dividend yield | N/A |
| 200-day MA | $1.39 | Market Cap | 121.23M |
ATOS Stock Price Chart Interactive Chart >
Atossa Genetics Inc. (ATOS) Company Bio
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
ATOS Price Returns
| 1-mo | -19.33% |
| 3-mo | -34.25% |
| 6-mo | -10.28% |
| 1-year | 23.11% |
| 3-year | -47.83% |
| 5-year | -41.10% |
| YTD | 9.09% |
| 2023 | 66.51% |
| 2022 | -66.97% |
| 2021 | 68.42% |
| 2020 | -39.49% |
| 2019 | 53.92% |
Loading social stream, please wait...